cause. The secondary experimental end point was treatment goal achievement (TGA), defined as an integrated outcome. Results: Among the 310 patients enrolled from 14 PAH centers, the median follow-up was 24.0 months. The 1-, 3-and 5-year survival rates were 92.1%, 84.8% and 72.9%, respectively. The 1-, 3-and 5-year TGA rates were 31.5%, 53.6% and 62.7%, respectively.Serositis, 6MWD >380 m and CI ≥2.5 L/min×m 2 were identified as independent prognostic factors of TGA. TGA within 5 years was identified as a factor associated with survival in patients with SLE-associated PAH (Figure 1 ).
Conclusions: TGA was associated with the long-term survival, which supports and provides evidence to the treat-to-target strategy in SLE-associated PAH. Early diagnosis, intervention and heart function preservation are priorities for better long-term outcomes. Methods: This is a retrospective analysis of data prospectively collected in a longitudinal observational cohort of LN patients. The conceptual definition of LLDAS is a state, which if sustained, is associated with good long-term outcomes. The operational definition of LLDAS is fulfilled when all of the following criteria are met: (1) SLE Disease Activity Index (SLEDAI-2 K) ≤4, with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no haemolytic anaemia or gastrointestinal activity; (2) no new features of lupus disease activity compared to the previous assessment; (3) a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI physician global assessment (PGA) (scale 0-3) ≤1; (4) a current prednisolone (or equivalent) dose ≤7,5 mg daily; and (5) well-tolerated standard maintenance doses of immunosuppressive drugs and approved biologic agents, excluding investigational drugs. The definition of LLDAS was applied to each patient for each visit; organ damage was calculated with the SLICC/DI score (SDI) at study entry and at last observation. Results: 294 patients were eligible for the study (89.79% females, mean age at first visit 31,4±11,9 years, mean disease duration at last visit 19,8±8,7 years). At last observation 219 patients (85,37%) were on treatment with glucocorticoids (GC) and/or immunomodulators. According with all the items of the definition, at last observation LLDAS was present in 146 patients (49,65%); among these, 37 patients (20,8%) maintained a stable LLDAS during the last 5 years of follow-up (LLDAS fulfilled for all visits). 68 patients (23,12%) accrued organ damage during the follow-up; in the cohort as a whole the mean increase in SDI was 0,4±0.67 resulting in a mean final SDI of 1,2±1,8. Patients who maintained LLDAS were younger (p<0,05), had a lower disease activity score at study entry (p<0,001) and were more likely GC-free at last observation (p<0,001). Patients who maintained LLDAS accrued less organ damage but this difference did not reach statistical significance. Conclusions: High percentage of patients fulfils the proposed definitions for LLDAS at last visit but only a minority maintained this state for all the followup period. A minimally acceptable disease activity state is associated with a successful GC tapering and, probably, better long-term outcomes. LLDAS was shown to be associated with protection from damage accrual. Objectives: a) To assess the accuracy of PI-US to diagnose ILD in pSS when compared to chest tomography (HRCT) (i.e gold standard imaging technique); b) to explore PI-US diagnostic value in early preclinical phases of lung involvement. Methods: PI-US was performed by a single operator using a MyLab-25 (Esaote), 10 MHz, 5 cm linear probe. PI was defined as the loss of the normal hyperechoic linear pleural contour (score 0-2: normal, minimal and major changes at each intercostal space). Abnormal findings at HRCT were quantified by an expert radiologist according to a semiquantitative score (0-2: absent, moderate, severe). Semi-quantitative scores assigned by PI-US and HRCT to 6 lung fields (2 for the anterior, 2 for postero-superior and 2 for postero-inferior chest surface) were compared. Total and partial scores (for each lung fields) were evaluated. For statistical analysis chi-square, Mann-Whitney test, R-Spearman, and ROC-curve analysis were used. Out of them, at the end of the diagnostic work -up, four new cases of HRCT-proven pSS-ILD were diagnosed. Their PI-US mean total score was significantly higher than that observed in non-ILD patients (48±18 vs 16±12, p=0.001) as well as their mean postero-inferior PI-US score (19±9 vs 6±5, p=0.003). The total PI-US and postero-inferior PI-US cut-off retrieved in the first part of the study (i.e. 28.5 and 12.5) allowed us to identify those patients with an HRCT-proven pSS-ILD with a SE of 75% and 100%, a SP of 95% and 89.5%, a PPV of 75% and 57% and a NPV of of 95% and 100%, respectively. Conclusions: Even if preliminary, this study demonstrated a strong correlation between PI-US and HRCT in the detection of ILD-pSS also in asymptomatic patients, opening new perspectives for the early non-invasive screening of lung involvement in pSS. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4368
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Results: Validation study phase (PI-US vs HRCT):
